Tolerance by selective in vivo expansion of foreign major histocompatibility complex-transduced autologous bone marrow

Transplantation

Volumn 80, Issue 3, 2005, Pages 362-369

  Zhang, Jia Lin ^a   Cai, Jin ^a   Walls, Shannon ^a   Jackson, John D ^a   Kuszynski, Charles A ^a   Zhao, Yong ^a   Pawliuk, Robert ^b   Leboukh, Philippe ^b   Fox, Ira J ^a,c  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c 983285 Nebraska Medical Center ^*  (United States)

Author keywords

Bone marrow transplantation; Chimerism; Gene therapy; Immune tolerance; Major histocompatibility antigens

Indexed keywords

COMPLEMENTARY DNA; DIHYDROFOLATE REDUCTASE; HLA A2 ANTIGEN; HLA B7 ANTIGEN; NITROBENZYLMERCAPTOPURINE RIBOSIDE 5' MONOPHOSPHATE; NITROBENZYLTHIOINOSINE; RETROVIRUS VECTOR; TRIMETREXATE; TYROSINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CHIMERA; CONTROLLED STUDY; CYTOTOXICITY; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; HEMATOPOIETIC STEM CELL; IMMUNOLOGICAL TOLERANCE; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PLASMID KA 274; PRIORITY JOURNAL; SKIN GRAFT; SPLEEN CELL; TRANSGENE; VESICULAR STOMATITIS VIRUS; VESICULAR STOMATITIS VIRUS G PSEUDOTYPED RECOMBINANT RETROVIRUS; VIRUS RECOMBINANT;

ANIMALS; BONE MARROW CELLS; BONE MARROW TRANSPLANTATION; CELL TRANSPLANTATION; DNA, COMPLEMENTARY; FLOW CYTOMETRY; GRAFT REJECTION; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELLS; HLA-A2 ANTIGEN; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTATION; POLYMERASE CHAIN REACTION; RETROVIRIDAE; SKIN TRANSPLANTATION; TIME FACTORS;

EID: 23744474789     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000165791.39723.a1     Document Type: Article

References (50)

1. Ildstad ST, Sachs DH. Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts. Nature 1984; 307: 168.
2. Ildstad ST, Wren SM, Bluestone JA, et al. Characterization of mixed allogeneic chimeras. Immunocompetence, in vitro reactivity, and genetic specificity of tolerance. J Exp Med 1985; 162: 231.
3. Bracy JL, Sachs DH, Iacomini J. Inhibition of xenoreactive natural antibody production by retroviral gene therapy. Science 1998; 281: 1845.
4. Schumacher IK, Newberg MH, Jackson JD, et al. Use of gene therapy to suppress the antigen-specific immune responses in mice to an HLA antigen. Transplantation 1996; 62: 831.
5. Bagley J, Tian C, Sachs DH, et al. Induction of T-cell tolerance to an MHC class I alloantigen by gene therapy. Blood 2002; 99: 4394.
6. Wong W, Billing JS, Stranford SA, et al. Retroviral transfer of donor MHC class I or MHC class II genes into recipient bone marrow cells can induce operational tolerance to alloantigens in vivo. Hum Gene Ther 2003; 14: 577.
7. Sykes M, Sachs DH, Nienhuis AW, et al. Specific prolongation of skin graft survival following retroviral transduction of bone marrow with an allogeneic major histocompatibility complex gene. Transplantation 1993; 55: 197.
8. Sonntag KC, Emery DW, Yasumoto A, et al. Tolerance to solid organ transplants through transfer of MHC class II genes. J Clin Invest 2001; 107: 65.
9. Malech HL, Maples PB, Whiting-Theobald N, et al. Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. Proc Natl Acad Sci U S A 1997; 94 (22):12133.
10. Cowan KH, Moscow JA, Huang H, et al. Paclitaxel chemotherapy after autologous stem-cell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resistance complementary DNA (MDR1) in metastatic breast cancer patients. Clin Cancer Res 1999; 5: 1619.
11. Moscow JA, Huang H, Carter C, et al. Engraftment of MDR1 and NeoR gene-transduced hematopoietic cells after breast cancer chemotherapy. Blood 1999; 94: 52.
12. Lewis PF, Emerman M. Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus. J Virol 1994; 68: 510.
13. Challita PM, Kohn DB. Lack of expression from a retroviral vector after transduction of murine hematopoietic stem cells is associated with methylation in vivo. Proc Natl Acad Sci U S A 1994; 91: 2567.
14. Hanawa H, Kelly PF, Nathwani AC, et al. Comparison of various envelope proteins for their ability to pseudotype lentiviral vectors and transduce primitive hematopoietic cells from human blood. Mol Ther 2002; 5:242.
15. Naldini L, Blomer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272: 263.
16. Imren S, Fabry ME, Westerman KA, et al. High-level beta-globin expression and preferred intragenic integration after lentiviral transduction of human cord blood stem cells. J Clin Invest 2004; 114: 953.
17. + CD38- bone marrow and cord blood-derived SCID-repopulating cells with third-generation lentiviral vectors. Mol Ther 2000; 1: 566.
18. Huhn RD, Tisdale JF, Agricola B, et al. Retroviral marking and transplantation of rhesus hematopoietic cells by nonmyeloablative conditioning. Hum Gene Ther 1999; 10: 1783.
19. Hacein-Bey-Abina S, Le Deist F, Carlier F, et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 2002; 346: 1185.
20. Sorrentino BP. Gene therapy to protect haematopoietic cells from cytotoxic cancer drugs. Nat Rev Cancer 2002; 2: 431.
21. Jin L, Siritanaratkul N, Emery DW, et al. Targeted expansion of genetically modified bone marrow cells. Proc Natl Acad Sci U S A 1998; 95: 8093.
22. Zhao S, Zoller K, Masuko M, et al. JAK2, complemented by a second signal from c-kit or flt-3, triggers extensive self-renewal of primary multipotential hemopoietic cells. Embo J 2002; 21: 2159.
23. Antonchuk J, Sauvageau G, Humphries RK. HOXB4-induced expansion of adult hematopoietic stem cells ex vivo. Cell 2002; 109: 39.
24. Sorrentino BP, Brandt SJ, Bodine D, et al. Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. Science 1992; 257: 99.
25. Licht T, Haskins M, Henthorn P, et al. Drug selection with paclitaxel restores expression of linked IL-2 receptor gamma -chain and multidrug resistance (MDR1) transgenes in canine bone marrow. Proc Natl Acad Sci U S A 2002; 99: 3123.
26. Allay JA, Persons DA, Galipeau J, et al. In vivo selection of retrovirally transduced hematopoietic stem cells. Nat Med. 1998; 4: 1136.
27. Davis BM, Koc ON, Gerson SL. Limiting numbers of G156A O(6)-methylguanine-DNA methyltransferase-transduced marrow progenitors repopulate nonmyeloablated mice after drug selection. Blood 2000; 95: 3078.
28. Ragg S, Xu-Welliver M, Bailey J, et al. Direct reversal of DNA damage by mutant methyltransferase protein protects mice against dose-intensified chemotherapy and leads to in vivo selection of hematopoietic stem cells. Cancer Res 2000; 60: 5187.
29. Sawai N, Zhou S, Vanin EF, et al. Protection and in vivo selection of hematopoietic stem cells using temozolomide, O6-benzylguanine, and an alkyltransferase-expressing retroviral vector. Mol Ther 2001; 3: 78.
30. Antonchuk J, Sauvageau G, Humphries RK. HOXB4 overexpression mediates very rapid stem cell regeneration and competitive hematopoietic repopulation. Exp Hematol 2001; 29: 1125.
31. Allay JA, Spencer HT, Wilkinson SL, et al. Sensitization of hematopoietic stem and progenitor cells to trimetrexate using nucleoside transport inhibitors. Blood 1997; 90: 3546.
32. Le AX, Bernhard EJ, Holterman MJ, et al. Cytotoxic T cell responses in HLA-A2.1 transgenic mice. Recognition of HLA alloantigens and utilization of HLA-A2.1 as a restriction element. J Immunol 1989; 142: 1366.
33. Pawliuk R, Eaves CJ, Humphries RK. Sustained high-level reconstitution of the hematopoietic system by preselected hematopoietic cells expressing a transduced cell-surface antigen. Hum Gene Ther 1997; 8: 1595.
34. Pawliuk R, Westerman KA, Fabry ME, et al. Correction of sickle cell disease in transgenic mouse models by gene therapy. Science 2001; 294: 2368.
35. Ory DS, Neugeboren BA, Mulligan RC. A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. Proc Natl Acad Sci U S A 1996; 93: 11400.
36. Fox IJ, Athan E, Fisher J, et al. Use of gene therapy to induce human-mouse xenogeneic chimerism. Surgery 1993; 114: 174.
37. Tsujisaki M, Sakaguchi K, Igarashi M, et al. Fine specificity and idiotype diversity of the murine anti-HLA-A2, A28 monoclonal antibodies CR11-351 and KS1. Transplantation 1988; 45: 632.
38. Lynch TP, Paran JH, Paterson AR. Therapy of mouse leukemia L1210 with combinations of nebularine and nitrobenzylthioinosine 5′-monophosphate. Cancer Res 1981; 41: 560.
39. Epstein SL, Ozato K, Sachs DH. Blocking of allogeneic cell-mediated lympholysis by monoclonal antibodies to H-2 antigens. J Immunol 1980; 125: 129.
40. Crumpacker DB, Alexander J, Cresswell P, et al. Role of endogenous peptides in murine allogenic cytotoxic T cell responses assessed using transfectants of the antigen-processing mutant 174xCEM.T2. J Immunol 1992; 148: 3004.
41. Engelhard VH, Le AX, Holterman MJ. Species-specific structural differences in the alpha 1 + alpha 2 domains determine the frequency of murine cytotoxic T cell precursors stimulated by human and murine class I molecules. J Immunol 1988; 141: 1835.
42. Billingham RE, Silvers WK. The induction of tolerance of skin homografts in rats with pooled cells from multiple donors. J Immunol 1959; 83: 667.
43. Fraser CC, Sykes M, Lee RS, et al. Specific unresponsiveness to a retrovirally-transferred class I antigen is controlled through the helper pathway. J Immunol 1995; 154: 1587.
44. Finer MH, Dull TJ, Qin L, et al. kat: a high-efficiency retroviral transduction system for primary human T lymphocytes. Blood 1994; 83:43.
45. Akashi K, Traver D, Miyamoto T, et al. A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature 2000; 404: 193.
46. Persons DA, Allay JA, Bonifacino A, et al. Transient in vivo selection of transduced peripheral blood cells using antifolate drug selection in rhesus macaques that received transplants with hematopoietic stem cells expressing dihydrofolate reductase vectors. Blood 2004; 103: 796.
47. Tisdale JF, Hanazono Y, Sellers SE, et al. Ex vivo expansion of genetically marked rhesus peripheral blood progenitor cells results in diminished long-term repopulating ability. Blood 1998; 92: 1131.
48. Kiem HP, Andrews RG, Morris J, et al. Improved gene transfer into baboon marrow repopulating cells using recombinant human fibronectin fragment CH-296 in combination with interleukin-6, stem cell factor, FLT-3 ligand, and megakaryocyte growth and development factor. Blood 1998; 92: 1878.
49. Mahmud N, Devine SM, Weller KP, et al. The relative quiescence of hematopoietic stem cells in nonhuman primates. Blood 2001; 97: 3061.
50. Cheshier SH, Morrison SJ, Liao X, et al. In vivo proliferation and cell cycle kinetics of long-term self-renewing hematopoietic stem cells. Proc Natl Acad Sci U S A 1999; 96: 3120.